Occult central nervous system involvement in patients with metastatic breast cancer

Prevalence, predictive factors and impact on overall survival

Kathy Miller, Tess Weathers, L. G. Haney, R. Timmerman, M. Dickler, J. Shen, G. W. Sledge

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

Background: As screening central nervous system (CNS) imaging is not routinely performed, the incidence and clinical relevance of occult CNS metastases in advanced breast cancer is unknown. Patients and methods: All patients screened for participation in one of four clinical trials were included; each of the trials excluded patients with known CNS involvement and required screening CNS imaging. A cohort of breast cancer patients with symptomatic CNS metastases was identified from the IU Cancer Center Tumor Registry for comparison. Results: From November 1998 to August 2001, 155 screening imaging studies were performed. Twenty-three patients (14.8%) had occult CNS metastases. HER-2 overexpression (P=0.02) and number of metastatic sites (P=0.03) were predictive of CNS involvement by multivariate analysis. Median survival from time of metastasis (1.78 versus 2.76 years; P<0.0001) and from screening (4.67 versus 10.4 months; P=0.0013) was shorter in patients with than without occult CNS metastasis. Survival among patients with occult CNS metastasis was similar to patients with symptomatic CNS disease. Conclusions: Patients with CNS involvement, whether occult or symptomatic, have an impaired survival. Occult CNS metastasis is relatively common, but impact on survival of treating occult CNS disease in patients with progressive systemic metastases is questionable.

Original languageEnglish
Pages (from-to)1072-1077
Number of pages6
JournalAnnals of Oncology
Volume14
Issue number7
DOIs
StatePublished - Jul 1 2003

Fingerprint

Central Nervous System
Breast Neoplasms
Survival
Neoplasm Metastasis
Central Nervous System Diseases
Patient Participation
Registries
Neoplasms
Multivariate Analysis
Clinical Trials
Incidence

Keywords

  • Breast cancer
  • Central nervous system
  • Metastasis
  • Natural history

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Occult central nervous system involvement in patients with metastatic breast cancer : Prevalence, predictive factors and impact on overall survival. / Miller, Kathy; Weathers, Tess; Haney, L. G.; Timmerman, R.; Dickler, M.; Shen, J.; Sledge, G. W.

In: Annals of Oncology, Vol. 14, No. 7, 01.07.2003, p. 1072-1077.

Research output: Contribution to journalArticle

@article{e02df729e4de40aa924c1dff6dc26a81,
title = "Occult central nervous system involvement in patients with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival",
abstract = "Background: As screening central nervous system (CNS) imaging is not routinely performed, the incidence and clinical relevance of occult CNS metastases in advanced breast cancer is unknown. Patients and methods: All patients screened for participation in one of four clinical trials were included; each of the trials excluded patients with known CNS involvement and required screening CNS imaging. A cohort of breast cancer patients with symptomatic CNS metastases was identified from the IU Cancer Center Tumor Registry for comparison. Results: From November 1998 to August 2001, 155 screening imaging studies were performed. Twenty-three patients (14.8{\%}) had occult CNS metastases. HER-2 overexpression (P=0.02) and number of metastatic sites (P=0.03) were predictive of CNS involvement by multivariate analysis. Median survival from time of metastasis (1.78 versus 2.76 years; P<0.0001) and from screening (4.67 versus 10.4 months; P=0.0013) was shorter in patients with than without occult CNS metastasis. Survival among patients with occult CNS metastasis was similar to patients with symptomatic CNS disease. Conclusions: Patients with CNS involvement, whether occult or symptomatic, have an impaired survival. Occult CNS metastasis is relatively common, but impact on survival of treating occult CNS disease in patients with progressive systemic metastases is questionable.",
keywords = "Breast cancer, Central nervous system, Metastasis, Natural history",
author = "Kathy Miller and Tess Weathers and Haney, {L. G.} and R. Timmerman and M. Dickler and J. Shen and Sledge, {G. W.}",
year = "2003",
month = "7",
day = "1",
doi = "10.1093/annonc/mdg300",
language = "English",
volume = "14",
pages = "1072--1077",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Occult central nervous system involvement in patients with metastatic breast cancer

T2 - Prevalence, predictive factors and impact on overall survival

AU - Miller, Kathy

AU - Weathers, Tess

AU - Haney, L. G.

AU - Timmerman, R.

AU - Dickler, M.

AU - Shen, J.

AU - Sledge, G. W.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Background: As screening central nervous system (CNS) imaging is not routinely performed, the incidence and clinical relevance of occult CNS metastases in advanced breast cancer is unknown. Patients and methods: All patients screened for participation in one of four clinical trials were included; each of the trials excluded patients with known CNS involvement and required screening CNS imaging. A cohort of breast cancer patients with symptomatic CNS metastases was identified from the IU Cancer Center Tumor Registry for comparison. Results: From November 1998 to August 2001, 155 screening imaging studies were performed. Twenty-three patients (14.8%) had occult CNS metastases. HER-2 overexpression (P=0.02) and number of metastatic sites (P=0.03) were predictive of CNS involvement by multivariate analysis. Median survival from time of metastasis (1.78 versus 2.76 years; P<0.0001) and from screening (4.67 versus 10.4 months; P=0.0013) was shorter in patients with than without occult CNS metastasis. Survival among patients with occult CNS metastasis was similar to patients with symptomatic CNS disease. Conclusions: Patients with CNS involvement, whether occult or symptomatic, have an impaired survival. Occult CNS metastasis is relatively common, but impact on survival of treating occult CNS disease in patients with progressive systemic metastases is questionable.

AB - Background: As screening central nervous system (CNS) imaging is not routinely performed, the incidence and clinical relevance of occult CNS metastases in advanced breast cancer is unknown. Patients and methods: All patients screened for participation in one of four clinical trials were included; each of the trials excluded patients with known CNS involvement and required screening CNS imaging. A cohort of breast cancer patients with symptomatic CNS metastases was identified from the IU Cancer Center Tumor Registry for comparison. Results: From November 1998 to August 2001, 155 screening imaging studies were performed. Twenty-three patients (14.8%) had occult CNS metastases. HER-2 overexpression (P=0.02) and number of metastatic sites (P=0.03) were predictive of CNS involvement by multivariate analysis. Median survival from time of metastasis (1.78 versus 2.76 years; P<0.0001) and from screening (4.67 versus 10.4 months; P=0.0013) was shorter in patients with than without occult CNS metastasis. Survival among patients with occult CNS metastasis was similar to patients with symptomatic CNS disease. Conclusions: Patients with CNS involvement, whether occult or symptomatic, have an impaired survival. Occult CNS metastasis is relatively common, but impact on survival of treating occult CNS disease in patients with progressive systemic metastases is questionable.

KW - Breast cancer

KW - Central nervous system

KW - Metastasis

KW - Natural history

UR - http://www.scopus.com/inward/record.url?scp=0042200720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042200720&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdg300

DO - 10.1093/annonc/mdg300

M3 - Article

VL - 14

SP - 1072

EP - 1077

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -